REVYPEEL®: The Next Generation of Needle-Free Bio-Revitalization

The breakthrough Class IIa medical device that is transforming the field of skin rejuvenation

Bologna, Italy – May 2025 – MBE, a trusted innovator in medical-aesthetic solutions, proudly presents REVYPEEL®, the breakthrough Class IIa medical device that is transforming the field of skin rejuvenation.
Unlike traditional treatments, REVYPEEL® delivers powerful biorevitalization without injections, combining efficacy, safety, and patient comfort in a single protocol. Its exclusive formulation—Trichloroacetic Acid (TCA), Mandelic Acid, and Kojic Acid—ensures profound stimulation and renewal of the skin while avoiding surface irritation.
Clinically proven to target photo- and chrono-aging, acne and acne scars, dyschromia, stretch marks, and deep or superficial scars, REVYPEEL® provides visible results from the very first session.
Available in two tailored versions—REVYPEEL® LOW and REVYPEEL® HIGH —the treatment adapts to patient needs, from fine wrinkles and discolorations to deep scars and severe acne.
Key Advantages:
- Needle-Free: No injections required.
- All-Season: Safe to use year-round.
- Universal: Suitable for all ages and skin phototypes (I–VI).
- No Frost Effect: Unlike traditional TCA peels.
- Fast & Effective: Immediate results with no downtime.

“REVYPEEL® represents the perfect synergy between science and beauty,” said Isabella Guillaume. “It gives medical professionals and aesthetic practitioners a versatile tool that not only restores youthful skin but also ensures patient satisfaction thanks to its safety profile and visible, long-lasting results.”
Proven Results
Before-and-after studies confirm its effectiveness: reduction of fine lines, improvement in skin texture, lightening of pigmentation, smoothing of scars, and a radiant, lifted appearance of the skin. Further outstanding results will be unveiled at the upcoming IMCAS Congress in Paris, January 2026.